The NCI Board of Scientific Advisors approved four new concepts and five reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board Dec. 2-3. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not […]
Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a…
Catch up with our live social media coverage of treatments for R/R AML, maintenance therapy, and mutation- and MRD-informed decisions from the 66th ASH Annual…
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, comments on the value of non-T-depleted haploidentical transplantation in patients with secondary acute myeloid leukemia (AML)…
Icro Meattini, MD, University of Florence, Florence, Italy, comments on the results of the FAST-Forward trial (ISRCTN19906132), stating that ultra-hypofractionated radiotherapy, as per the trial,…
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized…
IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
Daratumumab and lenalidomide improved survival outcomes over lenalidomide and dexamethasone in frail patients with newly diagnosed MM.
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
